AI
CRNX

Atria Investments’s Crinetics Pharmaceuticals CRNX Stock Holding History

Atria Investments’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$213K Buy
+5,692
New +$212K ﹤0.01% 2039
2026
Q1 		– Sell
-5,139
Closed -$239K – 2064
2025
Q4 		$239K Buy
5,139
+52
+1% +$2.31K ﹤0.01% 1875
2025
Q3 		$212K Buy
+5,087
New +$163K ﹤0.01% 1919

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JT
Jupiter Topco New York $245B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Atria Investments's CRNX Position: Q2 2026 in Review

Atria Investments opened a new position in Crinetics Pharmaceuticals (CRNX) in Q2 2026: 5,692 shares worth $213K. The stake represents ﹤0.01% of the portfolio and ranks #2039 among its holdings. This is a return to the name: Atria Investments previously reported a position in CRNX as recently as Q4 2025.

Atria Investments first reported a position in CRNX in Q3 2025 and has held it in 3 quarters since. The position peaked at $239K in Q4 2025. 267 funds tracked by Wall St. Rank hold CRNX as of Q2 2026.

  • Atria Investments held 5,692 shares of Crinetics Pharmaceuticals worth $213K as of Q2 2026.
  • Crinetics Pharmaceuticals was a new Atria Investments position in Q2 2026.
  • Crinetics Pharmaceuticals made up ﹤0.01% of Atria Investments's portfolio in Q2 2026, its #2039 holding.
  • Atria Investments first reported a position in Crinetics Pharmaceuticals in Q3 2025 and has held it in 3 quarters since.
  • Atria Investments's Crinetics Pharmaceuticals position peaked at $239K in Q4 2025.
  • 267 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q2 2026.

Based on Atria Investments's 13F filing for Q2 2026, filed 28 Jul 2026.